Selling tirzepatide on TikTok: what this video gets wrong

What's this video probably claiming?

Based on the caption and hashtags, @tonianthony777 appears to be using a personal 60-pound weight loss as a sales pitch for tirzepatide, a dual GIP/GLP-1 receptor agonist sold under the brand names Mounjaro and Zepbound. The implicit message is straightforward: this drug produced dramatic results for me, and you can buy it directly from me. The post doesn't mention a prescription, a physician, a compounding pharmacy, or any regulatory context. That silence is doing a lot of work. The creator is essentially presenting themselves as both a success story and a vendor, which is a combination that should immediately raise flags for anyone thinking critically about what they're actually being offered.

At 49,700 views, this content is reaching a meaningful audience of people who may be genuinely struggling with weight and looking for accessible solutions. The emotional weight of a 60-pound loss is real. The sales mechanism being deployed around it is not straightforward.

What does the science actually show?

Tirzepatide's efficacy data is genuinely impressive, and that's part of what makes this kind of content so effective and so potentially misleading. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), participants on the highest dose of 15 mg weekly lost a mean of 20.9% of body weight over 72 weeks, compared to 3.1% in the placebo group. That's not a trivial result. For someone starting at 300 pounds, that could plausibly approach 60 pounds lost.

But those results come with context that gets stripped out entirely in a TikTok caption. SURMOUNT-1 participants received structured dietary counseling and lifestyle intervention alongside the drug. Adverse events, primarily gastrointestinal, led to discontinuation in a meaningful subset of participants. The drug requires medical supervision, dose titration starting at 2.5 mg weekly, and ongoing monitoring. A 60-pound loss is a possible outcome under controlled conditions. It is not a guaranteed result from an unregulated transaction with a stranger online.

Where does the social media noise diverge from clinical reality?

The gap here is almost entirely about access and safety framing. Social media weight loss content consistently presents outcomes without presenting the infrastructure required to achieve them safely. A few specific divergences worth flagging:

• Tirzepatide is a Schedule III controlled substance in some jurisdictions and requires a prescription everywhere in the United States. Selling it without a prescription is illegal under federal law.
• What gets sold as "tirzepatide" through informal channels may be compounded tirzepatide, research-grade peptide, or something else entirely. The FDA has issued multiple warnings about compounded semaglutide and tirzepatide products, noting they cannot verify identity, potency, or sterility.
• Individual weight loss results are driven by baseline weight, adherence, diet, activity, and metabolic factors. A 60-pound loss is a best-case-range outcome, not a standard expectation.
• Withdrawal and weight regain are well-documented. Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed significant weight regain after stopping semaglutide, and similar dynamics apply to tirzepatide.

What should you actually know?

If you're considering tirzepatide for weight loss, the drug has real clinical support. The mechanism is solid, the trial data is strong, and for many patients with obesity or type 2 diabetes, it represents a meaningful therapeutic option. That part is not in dispute.

What is in dispute is whether buying it from a TikTok creator is a reasonable path to that outcome. It almost certainly is not. You have no way to verify the identity or purity of what you'd be purchasing, no medical supervision, no dose titration protocol, and no follow-up care. The FDA specifically warned in 2023 and 2024 about compounded GLP-1 products that have caused hospitalizations due to dosing errors, often because patients self-administered incorrect amounts without guidance.

The 60-pound transformation is being used as marketing collateral for an unregulated transaction. The transformation may be genuine. The sales arrangement almost certainly violates federal law. Those two things can both be true at the same time.